TITLE:
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

CONDITION:
Cytomegalovirus Retinitis

INTERVENTION:
Ganciclovir

SUMMARY:

      To provide oral ganciclovir to patients who require maintenance for control of
      cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for
      long-term administration of intravenous drugs.
    

DETAILED DESCRIPTION:

      Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of
      enrollment will receive 2 months of study drug and undergo follow-up.
    

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  AIDS.

          -  Stable CMV retinitis.

          -  Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days.

          -  No permanent central IV catheter at present.

          -  Had a permanent central IV catheter removed two or more times within the past 6
             months due to catheter infection or thrombosis.

          -  Consent of guardian if less than legal age of consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Require continuation of concomitant medications precluded by this protocol.

        Concurrent Medication:

        Excluded:

          -  Intravitreal anti-CMV treatment.

          -  Any other concomitant medications precluded by the protocol.

        Patients with the following prior condition are excluded:

        History of hypersensitivity to acyclovir or ganciclovir.
      
